Vyvanse vs. Adderall: Timing, Food, the Crash, and Misuse

Vyvanse and Adderall are the two amphetamine stimulants most people with ADHD end up choosing between. Once either one is working, the brain is dealing with amphetamine. The difference is how it gets there.

Adderall's amphetamine salts are active as soon as they dissolve. Vyvanse is a molecule your blood has to unlock first. Its active drug peaks later than immediate-release Adderall's, and it is the only one of the three products whose label tracks the effect hour by hour, out to 14 hours in adults. That unlocking step also limits what crushing or snorting it can do, though not whether it can be misused.

Since 2022 there has also been a less clinical difference: which one the pharmacy can fill.

How Vyvanse and Adderall work

Per their labels, amphetamines block the reuptake of norepinephrine and dopamine and increase their release, so more of those two signals stays between brain cells. The labels add that exactly how this treats ADHD is not known. The difference between the two products is the delivery.

Adderall needs no conversion. Its four amphetamine salts dissolve, and the blood sees a 3-to-1 mix of d-amphetamine and l-amphetamine.

Vyvanse is dextroamphetamine with the amino acid lysine attached. In that form it does nothing. Its label says the conversion happens primarily in the blood, through red blood cells. Lisdexamfetamine itself has a plasma half-life of under an hour; the dextroamphetamine it leaves behind has a half-life of roughly 10 to 11 hours in adults.

Food matters little for Vyvanse. Per the label, a high-fat meal or yogurt did not change how much dextroamphetamine reached the blood; it delayed the peak by up to about an hour. For Adderall XR, a high-fat meal pushes the peak back by about 2.5 hours.

Does Vyvanse give you energy like Adderall?

The alertness comes from the same molecule. Once Vyvanse is converted, the brain is seeing dextroamphetamine, the main component of Adderall.

What differs is the slope. Immediate-release Adderall peaks around three hours after a dose; the dextroamphetamine from Vyvanse peaks closer to four. One pediatric classroom study in the Vyvanse label found no significant effect at one hour and a significant effect from hour two through hour twelve.

Does Vyvanse feel different than Adderall?

Two measurable things differ: the peak comes later than with immediate-release Adderall, and Vyvanse delivers only the d-form while about a quarter of Adderall's amphetamine is the l-form. Neither label compares how the two feel.

Timing and the crash

People use "the crash" for the stretch when a dose wears off, often describing tiredness, low mood, or irritability. The labels do not use the word or measure it. What they describe is different: withdrawal, including fatigue and dysphoric mood, after stopping abruptly or cutting the dose following prolonged use.

What the labels do show is the shape of the curve. A short-acting tablet taken two or three times a day produces several rises and falls in blood level; a once-daily product spreads the release across one longer curve. Immediate-release Adderall is built around that arc: first dose on waking, further doses at intervals of 4 to 6 hours. Adderall XR stretches the curve with two bead types; its label describes one capsule as matching the plasma profile of the same total dose of the tablet split in two, taken four hours apart.

Vyvanse stretches it with chemistry. In the adult simulated-workplace study, attention was significantly better than placebo at every measurement from 2 through 14 hours after the morning dose. Neither Adderall label reports an hour-by-hour window like it. The long curve also means a late dose can wreck sleep: the Vyvanse label calls for a morning dose, both Adderall labels for dosing on awakening, and all three warn against afternoon or late-evening doses because of insomnia.

Vyvanse vs. Adderall side effects

The lists are nearly interchangeable because the active molecule nearly is. Both labels report average increases of about 2 to 4 mm Hg in blood pressure and 3 to 6 beats per minute in heart rate, and both carry the same warnings about sudden death in people with structural heart disease. The numbers below come from separate studies, not a head-to-head, so they cannot be scored against each other.

Adults with ADHD on Vyvanse: decreased appetite 27 percent (2 percent on placebo), insomnia 27 percent (8), dry mouth 26 percent (3), anxiety 6 percent (0). Adults on Adderall XR: dry mouth 35 percent (5 percent on placebo), loss of appetite 33 percent (3), insomnia 27 percent (13), headache 26 percent (13), anxiety 8 percent (5).

Which causes more irritability?

No label answers that, because no label compares them. In the Vyvanse adult trial, irritability led about 1 percent of patients (2 of 358) to stop; the Adderall XR adult trial reported agitation in 8 percent of patients against 5 percent on placebo. Those measure different things in different trials, so the two numbers cannot be lined up.

The serious warnings are identical. Both labels say stimulants can cause new psychotic or manic symptoms, which occurred in about 0.1 percent of stimulant-treated patients in pooled short-term studies, and that anxiety, psychosis, hostility, and aggression have been seen with stimulant misuse.

Appetite and weight loss

Both suppress appetite, and both labels say to monitor growth, including weight, in children. The Vyvanse adult trial reported average weight loss after four weeks of 2.8, 3.1, and 4.3 pounds across the three doses studied, against a half-pound gain on placebo. The Adderall XR adult trial listed weight loss in 10 percent of patients and none on placebo.

One line in the Vyvanse label deserves a plain reading: Vyvanse is approved for binge eating disorder and is explicitly not indicated or recommended for weight loss.

Misuse potential: why the prodrug matters

Both are Schedule II. In May 2023 the FDA required every prescription stimulant to carry the same updated boxed warning on misuse, abuse, addiction, and overdose, and to tell patients never to share their medication.

What the prodrug changes is how the risk behaves, not whether it exists: the Vyvanse label still describes a high potential for abuse and misuse. Snorting Vyvanse does not skip the conversion, which happens mainly in the blood; in one small study by the drug's manufacturer, in 18 healthy men, snorted lisdexamfetamine produced dextroamphetamine levels and peak timing similar to swallowing it. In the label's study of people with a history of drug abuse, a dose above Vyvanse's labeled maximum produced significantly less drug liking than a large dose of immediate-release d-amphetamine, and a still higher dose produced similar liking. Injected lisdexamfetamine still produced drug liking and euphoria above placebo. The labels warn that snorting or injecting any stimulant raises the risk of overdose and death.

Is there a Vyvanse to Adderall conversion?

Not an official one. Neither label contains a milligram-to-milligram conversion between the two products, and we are not going to publish one.

A milligram of Vyvanse is a milligram of lisdexamfetamine dimesylate, which includes the salt and the lysine that is split off in the blood. A milligram of Adderall is four amphetamine salts in a d and l mix. Equal numbers on the bottle are not equal doses of amphetamine.

That is also why "Is Vyvanse stronger than Adderall?" has no real answer. Strength depends on dose, and the doses are not comparable. What Vyvanse has is a longer labeled window, which is a separate claim.

The labels say something narrower than a conversion. Adderall XR's label gives adults one recommended dose whether they are starting treatment or switching from another medication, rather than a formula. Vyvanse's label gives one starting dose for everyone and says nothing specific about switching. Both describe adjusting the dose at about weekly intervals.

When one fits better than the other

NIMH puts it simply: sometimes a person has to try several medications or doses before finding the one that works. What follows are patterns prescribers weigh, not rules.

Start with the length of your day. A workday plus a commute and dinner is easier to cover with a 12-hour-plus curve than with tablets every four to six hours, and Vyvanse is the one with a documented number: its adult data runs to 14 hours, while Adderall XR's label states no duration in hours. Short shifts, or medication-free days, may favor the tablet's flexibility.

Binge eating disorder settles it in one direction. Vyvanse is the only one of the two with an FDA indication, for moderate to severe binge eating disorder in adults. In its two pivotal trials, patients on Vyvanse had between 1.35 and 1.66 fewer binge days per week than patients on placebo.

With a substance use history, a prescriber may lean toward the prodrug because of its lower drug-liking data, or away from stimulants entirely. The three-way guide to Ritalin, Adderall, and Vyvanse covers the non-stimulant options.

The stimulant shortage since 2022

FDA's drug shortage database first posted immediate-release amphetamine mixed salts tablets as in shortage on October 12, 2022, and lisdexamfetamine capsules on July 14, 2023. In July 2024, FDA asked the DEA to raise the manufacturing quota for lisdexamfetamine, citing a shortage of the active ingredient. As of October 2026, the mixed salts tablet and lisdexamfetamine capsules and chewables are all still listed as currently in shortage.

During the shortage, some people have been moved between these two, or to methylphenidate products such as Concerta, because of supply rather than a clinical reason. If you are starting or switching, it is worth asking the pharmacy which of the two it can fill before the prescription is written.

Why do people switch from Vyvanse to Adderall?

Often for reasons that have nothing to do with which molecule is better. The pharmacy cannot fill lisdexamfetamine that month, or the plan covers one generic and not the other. Some people want the shorter window the tablet allows. Others had side effects on one and not the other, which happens in both directions.

Why won't some doctors prescribe Vyvanse?

Often the reasons are not about Vyvanse specifically. Some clinicians do not prescribe Schedule II stimulants at all and refer to psychiatry. Some will not start one without a full ADHD evaluation and the abuse-risk assessment the boxed warning requires. And through the shortage, some have steered patients toward whatever the local pharmacy could stock.

When to get help

If your use has moved past the prescription, whether that means taking more than prescribed, using someone else's, or needing an escalating dose to function, it deserves professional help rather than shame; see our piece on prescription stimulant misuse and its mental health risks. If you have never been evaluated at all, start there. NIMH notes that some adults were never diagnosed as children and that it is never too late to seek a diagnosis; our guide to ADHD in adult women covers why it can be missed. Our Ritalin vs. Adderall guide covers the other common fork.

If someone has chest pain, shortness of breath, fainting, a seizure, severe agitation or paranoia, or cannot be woken after taking a stimulant, call 911. If someone took too much and has none of those signs, call Poison Help at 1-800-222-1222 right away. For a mental health crisis, call or text 988, free and confidential, any hour. For treatment referrals for substance use or mental health, the SAMHSA National Helpline at 1-800-662-4357 is free, confidential, and open 24/7, and FindTreatment.gov lets you search licensed programs near you.

Frequently asked questions

Is Vyvanse stronger than Adderall?

No. Milligram numbers on the two bottles measure different molecules, so they cannot be compared directly, and neither FDA label ranks one above the other. Longer-lasting is not the same as stronger.

Is there an official Vyvanse to Adderall conversion?

No. Neither prescribing label contains a milligram-to-milligram conversion between the products. Prescribers start the new medication at its labeled starting dose and re-titrate, usually at weekly intervals.

Which has fewer side effects, Vyvanse or Adderall?

The lists are nearly the same because both deliver amphetamine: decreased appetite, insomnia, dry mouth, anxiety, and a faster heart rate. The trial percentages come from separate studies, so neither label shows one product to be gentler.

Is Vyvanse harder to misuse than Adderall?

Not in the sense of being safe to misuse. Its label still describes a high potential for abuse and misuse, and it is a Schedule II amphetamine with the same boxed warning as Adderall. What differs is that red blood cells must convert it to dextroamphetamine, so crushing or snorting it does not skip that step, and the label's abuse studies found less drug liking than d-amphetamine at one high dose, with similar liking at a still higher dose. Snorting or injecting any stimulant raises the risk of overdose and death.

Can Vyvanse be used for weight loss?

No. Its label states that Vyvanse is not indicated or recommended for weight loss. The binge eating disorder approval measured binge days per week, not pounds lost.

Sources

• DailyMed. "Vyvanse (lisdexamfetamine dimesylate) prescribing information."
• DailyMed. "Adderall (amphetamine salts) prescribing information."
• DailyMed. "Adderall XR (amphetamine salts) extended-release prescribing information."
• DailyMed. Search results for amphetamine aspartate (generic tablets and extended-release capsules).
• U.S. Food and Drug Administration. "FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions." May 11, 2023.
• U.S. Food and Drug Administration. "2023 First Generic Drug Approvals."
• U.S. Food and Drug Administration. "Current and Resolved Drug Shortages and Discontinuations Reported to FDA."
• openFDA. Drug shortage records for lisdexamfetamine dimesylate capsules.
• openFDA. Drug shortage records for amphetamine mixed salts tablets.
• Drug Enforcement Administration. "Adjustment to the Aggregate Production Quota for Lisdexamfetamine and d-Amphetamine (for Conversion) for 2024." Federal Register, September 5, 2024.
• MedlinePlus. "Lisdexamfetamine."
• MedlinePlus. "Dextroamphetamine and Amphetamine."
• National Institute of Mental Health. "Attention-Deficit/Hyperactivity Disorder: What You Need to Know."
• Ermer JC, Dennis K, Haffey MB, et al. "Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men." Clinical Drug Investigation, 2011;31(6):357-370. Study by the manufacturer (Shire).
• National Institute on Drug Abuse. "What classes of prescription drugs are commonly misused?"
• Substance Abuse and Mental Health Services Administration. "National Helpline."